Arianna E. Kousari, Melissa P. Wilson, Kellie L. Hawkins, Mohamed Mehdi Bandali, Andrés F. Henao-Martínez, Edward M. Gardner, Kristine M. Erlandson
{"title":"艾滋病毒感染者从基于整合酶抑制剂或替诺福韦-阿拉非那胺的抗逆转录病毒疗法转为基于多拉韦林的抗逆转录病毒疗法后的体重变化","authors":"Arianna E. Kousari, Melissa P. Wilson, Kellie L. Hawkins, Mohamed Mehdi Bandali, Andrés F. Henao-Martínez, Edward M. Gardner, Kristine M. Erlandson","doi":"10.1080/25787489.2024.2339576","DOIUrl":null,"url":null,"abstract":"Weight gain has been well-described with integrase strand transfer inhibitors (INSTIs) and tenofovir alafenamide (TAF). Doravirine (DOR) has been identified as a relatively “weight-neutral” drug; h...","PeriodicalId":13165,"journal":{"name":"HIV Research & Clinical Practice","volume":"45 1","pages":""},"PeriodicalIF":1.7000,"publicationDate":"2024-06-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Weight change with antiretroviral switch from integrase inhibitor or tenofovir alafenamide-based to Doravirine-Based regimens in people with HIV\",\"authors\":\"Arianna E. Kousari, Melissa P. Wilson, Kellie L. Hawkins, Mohamed Mehdi Bandali, Andrés F. Henao-Martínez, Edward M. Gardner, Kristine M. Erlandson\",\"doi\":\"10.1080/25787489.2024.2339576\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Weight gain has been well-described with integrase strand transfer inhibitors (INSTIs) and tenofovir alafenamide (TAF). Doravirine (DOR) has been identified as a relatively “weight-neutral” drug; h...\",\"PeriodicalId\":13165,\"journal\":{\"name\":\"HIV Research & Clinical Practice\",\"volume\":\"45 1\",\"pages\":\"\"},\"PeriodicalIF\":1.7000,\"publicationDate\":\"2024-06-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"HIV Research & Clinical Practice\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/25787489.2024.2339576\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"HIV Research & Clinical Practice","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/25787489.2024.2339576","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
Weight change with antiretroviral switch from integrase inhibitor or tenofovir alafenamide-based to Doravirine-Based regimens in people with HIV
Weight gain has been well-described with integrase strand transfer inhibitors (INSTIs) and tenofovir alafenamide (TAF). Doravirine (DOR) has been identified as a relatively “weight-neutral” drug; h...
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
